DocumentsDate added
Original article
Sudipta Kar*
Sr. Lecturer, Department of Paedodontics & Preventive Dentistry, Guru Nanak Institute of Dental Sciences & Research, Kolkata 114, West Bengal, India
Address reprint requests to
*Sudipta Kar,
21F, Charakdanga Road, Uttarpara, Hooghly 712258,
West Bengal, India
Article citation: Sudipta K. A COMPARATIVE PREALENCE STUDY OF ORAL HABIT STATUS AMONG IVF AND SPONTANEOUSLY CONCEIVED CHILDREN OF WEST BENGAL. J Pharm Biomed Sci 2015;05(10):782–786. Available at www.jpbms.info
Objective In-Vitro fertilization is one of the modern treatments modality of infertility. Deleterious oral habits are the common problem often found by the dental surgeons during routine examination. Oral habits are repetitive behaviour in the oral cavity that exhibited in different ways like thumb sucking, lip sucking, nail biting, mouth breathing, tongue thrusting, handkerchief biting, etc. Development of oral habits may cause dentoalveolar and/or skeletal deformation in children and ultimately form, function, and aesthetics of orofacial region may be compromised.
Results The results showed that the PREVALENCE of oral habits in IVF children was 39.3%. Thumb sucking was relatively more common habit and seen in only 16.66% of IVF children.
Nail biting was found in 11.33%, handkerchief biting in 3.33%, and the result was significant at p < 0.05. Tongue thrusting (6%) and mouth breathing (2%) cases was relatively less common of IVF children and the result is not significant at p < 0.05 level. Presence of handkerchief biting is a unique finding of the present study.
Conclusion The deleterious oral habits restrict proper growth and development of orofacial structure of IVF children. So these kinds of habits should be interrupted and treated as early as possible.
KEYWORDS IVF children, oral habits, thumb sucking, mouth breathing, PREVALENCE, tongue thrusting, handkerchief biting
Key Messages: IVF children are more oral habit prone.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Subrat Chandra1, Sushil Kumar Shukla2*,Dushyant Gaur3 Pooja Gupta4
1Associate Professor, Department of Pathology, Ram Manohar Lohia Institute of Medical Sciences, Vibhuti Khand, Gomti Nagar, Lucknow, India
2Associate Professor, Department of Community Medicine, UP RIMSR, Saifai, Etawah, UP, India
3 Professor & Head, Department of Pathology, HIMS, Dehradun, India
4 Associate Professor, Department of Obs. & Gyn., UP RIMSR, Saifai, Etawah, UP, India
Address reprint requests to
*Dr. Sushil Kumar Shukla,
Associate Professor, Department of Community Medicine, UP RIMSR, Saifai,Etawah, UP, India
Article citation: Chandra S, Shukla S, Gaur D, Gupta P. A cross-sectional study to identify the proportion of anaplastic carcinoma in thyroid cancer cases reporting to HIMS, Dehradun, India. J Pharm Biomed Sci 2015;05(10):817–821.Available at www.jpbms.info
Abstract
Background Anaplastic carcinoma of the thyroid (ATC) is the most aggressive thyroid gland malignancy. Although ATC accounts for less than 2% of all thyroid cancers, it causes up to 40% of deaths from thyroid cancer. Anaplastic carcinoma consists partly or entirely of undifferentiated cells. This represents 10% of all thyroid carcinomas and this is the most aggressive neoplasm of this gland.
Objective To estimate the proportion of anaplastic carcinoma and its subtypes. Methods and Results We studied 150 cases out of which 15 were reported as thyroid malignancy. Anaplastic carcinomas are reported here in four cases of middle age 5th and 6th decay of their life, two male and two female 1:1 with history suggestive of hyperthyroidism in three cases and euthyroid in one case. The tumours were of variable size and showed large pleomorphic cells in clusters as well as in an isolated form. The femaleto- male ratio was approximately 3:1. Peak incidence occurs during the third to fourth decades of life. The age range of affected patients reportedly is 15–70 years.
Conclusion ATC is a very uncommon malignancy but in our study we found four cases and we confirmed it by histopathological examination.
KEYWORDS anaplastic carcinoma, thyroid cancer, neoplastic lesions, hyperthyroidism, euthyroid
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research,patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Case Report
Sunita Lawange1*,Ashok K Lawange2,Pravin Sapkal3
1 Anaesthesiology Fellowship in Pain Medicine, Ex-Associate Professor in Anaesthesiology, Consultant Pain Physician, Director, Ashwini Pain Clinic Mehadia Bhavan, Dhantoli, Lokmat Square,Nagpur, India
2 Orthopedics
3 Associate Professor, GMC, Akola
Address reprint requests to
* Dr. Sunita Lawange,
Ashwini Pain Clinic, Mehadia Bhavan, Dhantoli, Lokmat Square, Nagpur, India
Article citation: Lawange S, Lawange AK, Sapkal P. A multidisciplinary approach in managing Raynaud’s disease: a case report. J Pharm Biomed Sci 2015;05(10):787–790.
ABSTRACT Raynaud disease is a benign episodic digital vasospasm mainly of upper limbs, resulting in ischaemia other peripheral tissues. The chief complaints are constant excruciating pain, burning type, aching sensation in the affected extremity, can be unilateral or bilateral, and discolouration of finger tips along with allodynia and hyperalgesia.
A multidisciplinary approach is the key behind successful outcome of treatment which includes drugs, exercise, and interventions in form of diagnostic sympathetic blocks followed
by radiofrequency sympathectic denervation.
KEYWORDS vascular, sympathectomy, pain.
REFERENCES
1.James P. Rathmel, Atlas of Image Guided Intervention in Regional Anaesthesia and Pain Medicine. Wolters K, Lippincott Williams & Wilkins.
2.Waldman SD (ed). Atlas of Pain Management Injection Techniques. Philadelphia: WB Saunders Company; 2000.
3.Ballantyne J. The Massachusetts General Hospital Handbook of Pain Management. Philadelphia: Lippincott Williams & Wilkins; 2002.
4.van Kleef M, Mekhail N, van Zundert J. Evidence-based guidelines for interventional pain medicine according to clinical diagnoses. Pain Pract. 2009;9(4):247–51.
5.Ubbink DT, Vermeulen H. Spinal cord stimulation for nonreconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. 2005;20(3):CD004001.
6.Wigley FM. Clinical practice. Raynaud’s phenomenon. N Engl J Med. 2002;347:1001–8.
8.Pope JE. The diagnosis and treatment of Raynaud’s phenomenon: a practical approach. Drugs. 2007;67:517–25.
9.Cooke JP, Marshall JM. Mechanisms of Raynaud’s disease. Vasc Med. 2005;10:293–307.
10.Fontaine R, Kim M, Kieny R. [Surgical treatment of peripheral circulation disorders]. Helv Chir Acta. 1954;21:499–533.
11.Cross FW, Cotton LT. Chemical lumbar sympathectomy for ischemic rest pain. A randomized, prospective controlled clinical trial. Am J Surg. 1985;150:341–5.
12.Fyfe T, Quin RO. Phenol sympathectomy in the treatment of intermittent claudication: a controlled clinical trial. Br J Surg.1975;62:68–71.
13.Repealer van Driel O, Van Bockel J, Van Schilfgarde R. Lumbar sympathectomy for severe lower limb ischaemia: results and
analysis of factors influencing outcome. J Cardiovasc Surg.1998;29:310–4.
14.Keane FB. Phenol lumbar sympathectomy for severe arterial occlusive disease in the elderly. Br J Surg. 1977;64:519–21.
15.Jivegard LE, Augustinsson LE, Holm J, Risberg B, Ortenwall P. Effects of spinal cord stimulation (SCS) in patients with
inoperable severe lower limb ischaemia: a prospective randomised controlled study. Eur J Vasc Endovasc Surg. 1995;9:421–5.
16.Suy R, Gybels J, Van DH, Martin D, Van MR, Delaporte C. Spinal cord stimulation for ischaemic rest pain. The Belgian
randomized study. In: Horschs S, Claeys L, eds. Spinal Cord Stimulation: An Innovative Method in the Treatment of PVD. Darmstadt: Steinhoff; 1994. pp. 197–202.
17.Klomp HM, Spincemaille GH, Steyerberg EW, Habbema JD, van Urk H. Spinal-cord stimulation in critical limb ischaemia: a
randomised trial. ESES Study Group. Lancet. 1999;353:1040–44.
18.Broseta J, Barbera J, de Vera JA, et al. Spinal cord stimulation in peripheral arterial disease. A cooperative study. J Neurosurg. 1986;64:71–80.
19.van Eijs F, Stanton-Hicks M, Van Zundert J, et al. Evidence-based interventional pain medicine according to clinical diagnoses. 16. Complex regional pain syndrome. Pain Pract. 2011;11:70–87.
20.Devulder J, Suijlekom HV, Dongen RV, et al. Ischemic pain in the extremities and Raynaud’s phenomenon. Evidence-Based Medicine. 2011;11(5):483–90.
Source of funding: None.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Case Report
Amit Gupta1*, Puneet Ahuja2, Swyeta Jain Gupta3,Vivek Gautam4,Vivek Rai5
1Senior Lecturer, Department of Oral and Maxillofacial Pathology and Microbiology, I.T.S. Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
2 Prof & Head, Department of Oral and Maxillofacial Pathology and Microbiology, I.T.S. Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
3Senior Lecturer, Department of Periodontics and Implantology, I.T.S.Centre for Dental Studies and Research, Ghaziabad, Uttar Pradesh, India
4MDS,Prosthodontics (Private practitioner),Gautam Multispeciality Dental Clinic,P N Plaza Complex, Below Bank Of India,Sigra, Varanasi, Uttar Pradesh, India
5 MDS, Endodontics, Private Practitioner,Lucknow,Uttar Pradesh, India
Address reprint requests to
Dr. Amit Gupta,
Department of Oral and Maxillofacial Pathology and Microbiology,
I.T.S. Dental College, Hospital and Research Centre, Greater Noida, Uttar Pradesh, India
Article citation: Gupta A, Ahuja P,Gupta SJ, Gautam V, Rai V. Critical role of tumor marker biology in the assessment of radiotherapy as a therapeutic modality in oral squamous cell carcinoma. J Pharm Biomed Sci 2015;05(10):799–806. Available at www.jpbms.info
ABSTRACT Despite advances in oncology therapeutics and biomedical research that have transformed since the turn of this century and deepened our understanding of cancer hallmarks, resulting in the discovery and development of targeted therapies, the success rates of oncology drug development remain low. Opportunities have increased with the understanding of molecular basis of the cancer translating to the discovery, development and availability of targeted therapies that have brought meaningful benefit to patients with diverse malignancies. One of the most challenging aspects of head and neck oncology is the selection of the most appropriate treatment for an individual patient with squamous cell carcinoma. The encouraging results from neoadjuvant chemotherapy and radiotherapy for patients with larger tumours, call for the identification of new accurate predictors of response to radiotherapy so that the appropriate therapy can be tailored better for individual patients.
KEYWORDS radiotherapy, squamous cell carcinoma, tumour markers
REFERENCES
1.Bucci MK, Bevan A, Roach M 3rd. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin. 2005;55:117–34.
2.Chapman JD. Single-hit mechanism of tumour cell killing by radiation. Int J Radiat Biol. 2003;79(2):71–81.
3.Sinclair WK, Morton RA. Variations in X-ray response during the division cycle of partially synchronized Chinese hamster cells in culture. Nature. 1963;199:1158–60.
4.Vikram B, Strong EW, Shah JP, Spiro R. Failure in the neck following multimodality treatment for advanced head and neck cancer. Head Neck Surg. 1984;6(3):724–29.
5.Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol. 1996;40:197–223.
6.Littbrand B, Révész L. The effect of oxygen on cellular survival and recovery after radiation. Br J Radiol. 1969;42(504):914–24.
7.Martin L, Green B, Renshaw C, Lowe D, Rudland P, Leinster SJ. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer. 1997;76(8):1046–54.
8.Brun E, Zätterström U, Kjellén E, Zatterstrom U, Kjellen E, Wahlberg P, et al. Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas. Acta Oncol. 2001;40:491–6.
9.Shintani S, Kiyota A, Mihara M, Nakahara Y, Terakado N, Ueyama Y, et al. Association of preoperative radiation effect with tumour angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma. Jpn J Cancer Res. 2000;91(10):1051–7.
10.Aebersold DM, Beer KT, Laissue J, Hug S, Kollar A, Greiner RH, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Onocol Biol Phys. 2000;48:17–25.
11.Rosen EM, Fan S, Goldberg ID, Rockwell S. Biological basis of radiation sensitivity. Part 2: cellular and molecular determinants of radiosensitivity. Oncology (Williston Park). 2000;14(5):741–57; discussion 757–8.
12.Jayasurya R, Francis G, Kannan S, Lekshminarayanan K,Nalinakumari KR, Abraham T, et al. p53, p16 and cyclin D1: molecular determinants of response to radiotherapy treatment response in oral carcinoma. Int J Cancer. 2004;109(5):710–6.
13.Jeggo PA, Taccioli GE, Jackson SP. Menage à trios: double strand break repair, V(D)J recombination and DNA-PK. Bioassays.1995;17(11):949–57.
14.Gottlieb TM, Jackson S. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen.Cell. 1993;72(1):131–42.
15.Shintani S, Mihara M, Li C, Nakahara Y, Hino S, Nakashiro K, et al. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma.Cancer Sci. 2003;94(10):894–900.
16.Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications.Lancet Oncol. 2001;2(11):667–73.
17.Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13(1):18–32.
18.Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9(Suppl 1):2–10.
19.Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Onocol Biol Phys. 2001;49(2):427–33.
20.Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000;18(10):2046–52.
21.Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002;24:792–9.
22.Terakado N, Shintani S, Yano J, Chunnan L, Mihara M, Nakashiro K,Hamakawa H. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol. 2004;40(4):383–9. Nikitakis NG, Sauk JJ, Papanicolaou SI. The role of apoptosis in oral diseases: mechanisms; aberrations in neoplastic,autoimmune; infectious; hematologic and developmental diseases; and therapeutic options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(4):476–90.
24.Loro LL, Vintermyr OK, Liavaag PG, Johannessen AC. Oral squamous cell carcinoma is associated with decreased bcl-2/bax expressed ratio and increased apoptosis. Hum Pathol. 1999;30(9):1097–105.
25.Xie X, Clausen OP, Boysen M. Prognostic value of Bak expression in oral tongue squamous cell carcinomas. Oncol Rep. 2003;10(2):369–74.
26.Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer. 1999;86(6):913–20.
27.Vora HH, Shah NG, Patel DD, Trivedi TI, Chikhlikar PR. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis. J Surg Oncol. 2003;82(1):34–50.
28.Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11(4):689–708.
29.Yarden Y. The EGFR family and its ligands in human cancer:signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–S8.
30.Song JI, Grandis JR. STAT signaling in head and neck cancer.Oncogene. 2000;19(21):2489–95.
31.Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(8):1935–40.
32.Gee JM, Nicholson RI. Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res. 2003;5(3):126–9.
33.Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, et al.Enhanced radiosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiationand 5-FU-induced production of IL-6 and IL-8. Int J Cancer.2004;108(6):912–21.
34.Baselga J. The EGFR as a target for anticancer therapy—focus on cetuximab. Eur J Cancer. 2001;37(Suppl 4):S16–S22.
Source of funding: None.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original Article
Ahmed M. Hamdan*
Department of Pharmaceutics, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia
Liposomes are drug delivery systems that may increase the penetration of lipophilic compounds through the skin, enhancing their topical effect. Voriconazole (VRC) is a broad-spectrum trizole antifungal medication that is active against invasive aspergillosis, candidiasis and certain emerging fungal infections. In this study, we formulated different compositiosof liposomal preparations for VRC and we EVALUATED the physical characteristics of these preparations including vesicular shape, vesicular size, drug entrapment efficiency, drug loading capacity and drug release properties of VRC.
KEYWORDS antifungal, voriconazole (VRC), liposomes, formulation
Address reprint requests to
*Ahmed Mohsen Hamdan, Department of Pharmaceutics, Faculty of Pharmacy,University of Tabuk, Tabuk, KSA
E-mail: a_hamdan@ut.edu.sa
Article citation: Hamdan AM. Design,formulation and characterization of liposomal preparation of voriconazole (VRC). J Pharm Biomed Sci 2015;05(10):822–827. Available at www.jpbms.info
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: Deanship of Scientific Research (DSR), University of Tabuk, Tabuk,Saudi Arabia, under the grant number S/1436/0102.
Competing interest / Conflict of interest:
The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense. The manuscript is original and is not published or communicated for publication elsewhere either in part or full.
Acknowledgement: The authors would like to acknowledge financial support for this work from the Deanship of Scientific Research (DSR), University of Tabuk, Tabuk, Saudi Arabia, under the grant number S/1436/0102.